title: Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells.
abstract: Poorly differentiated and anaplastic thyroid cancers are aggressive and usually fatal neoplasms, despite aggressive treatment. We performed an in vitro study to assess the activity of gemcitabine (2',2' difluorodeoxycytidine), a new fluorinated nucleoside analogue, against three poorly differentiated human thyroid carcinoma cell lines (ARO, WRO, and NPA). Each cell line was exposed to increasing concentrations of gemcitabine (0.0003 to 3000 mumol/L) for 24, 48, and 72 hours. Maximal reduction in cell viability was seen after 72 hours of gemcitabine for all three cell lines as measured by 3-(4,5-dimethyl thiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) assay. NPA cells were more sensitive than the other two lines after 24 and 48 hours of exposure, but all cell lines were similarly sensitive at 72 hours. A cytotoxic effect was confirmed by DNA assay of adherent cells. IC50 concentrations for reduction in cell viability ranged from 0.731 and 0.986 mumol/L for each cell line after 72 hours of exposure. These concentrations are lower than serum levels in phase 1 clinical trials of gemcitabine for other malignancies. In summary, gemcitabine has activity against poorly differentiated thyroid cancer cell lines in vitro. In vivo studies using xenograft models are warranted to confirm these promising observations.
authors.affiliation: Section of Endocrinology, Washington Hospital Center, Washington, DC, USA. mxr9@mhg.edu
authors.forename: M D
authors.initials: MD
authors.lastname: Ringel
authors.forename: M
authors.initials: M
authors.lastname: Greenberg
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: N
authors.initials: N
authors.lastname: Hayre
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: D
authors.initials: D
authors.lastname: Priebat
authors.forename: M
authors.initials: M
authors.lastname: Saji
authors.forename: K D
authors.initials: KD
authors.lastname: Burman
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy*; D002454:Cell Differentiation; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009154:Mutation; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D016159:Tumor Suppressor Protein p53; D003841:Deoxycytidine; D000093542:Gemcitabine